Efficacy and safety of combining TACE with atezolizumab/bevacizumab versus TACE alone: a retrospective propensity score-matched cohort study in HBV-related hepatocellular carcinoma
Frontiers in Oncology · 29.06.2026 · 16
DOI: 10.3389/fonc.2026.1840779 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Oncology, online erschienen am 29.06.2026. Verfasst von Jie Feng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Second People's Hospital of China Three Gorges University, Yichang, Hubei, China. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Transarterial chemoembolization (TACE) is an established treatment for intermediate to advanced hepatocellular carcinoma (HCC) in China, where chronic hepatitis B virus (HBV) infection constitutes the primary etiology. Although the use of TACE combined with atezolizumab/bevacizumab (TACE+TA) is increasing, robust evidence regarding its efficacy and safety—including the risk of HBV reactivation—remains limited in this etiologically distinct population.
Methods
This retrospective analysis included 246 patients with HBV-related HCC treated between 2020 and 2024. Patients were stratified according to the treatment received: TACE monotherapy (n = 113) or TACE+TA (n = 133). The primary endpoints were overall survival (OS) and progression-free survival (PFS). Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). To minimize selection bias, a 1:1 propensity score matching (PSM) analysis was performed.
Results
After matching, patients receiving TACE+TA achieved superior outcomes compared with TACE monotherapy, with prolonged median OS (19 vs. 13 months; P < 0.001) and extended median PFS (8 vs. 6 months; P = 0.004). In the unmatched cohort, the objective response rate was also higher in the combination group (48.1% vs. 30.0%; P = 0.004). Independent risk factors for worse OS included elevated baseline HBV-DNA load, advanced BCLC stage, and receipt of monotherapy. Notably, the combination therapy group experienced a higher incidence of adverse events, particularly HBV reactivation (8.3% vs. 1.8%; P = 0.023), immune-mediated hepatitis, pneumonitis, and thrombocytopenia.
Conclusions
In patients with HBV-related HCC, TACE+TA confers a significant survival advantage over TACE monotherapy, albeit with an increased risk of HBV reactivation and immune-related adverse events. This finding underscores the need for rigorous antiviral prophylaxis and close monitoring in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, The Second People's Hospital of China Three Gorges University, Yichang, Hubei, China.
- Department of Ultrasound Medicine, The Second People's Hospital of China Three Gorges University, Yichang, Hubei, China.
Zitieren
APA
Feng, J., Lin, G., & Wang, Y. (2026). Efficacy and safety of combining TACE with atezolizumab/bevacizumab versus TACE alone: a retrospective propensity score-matched cohort study in HBV-related hepatocellular carcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1840779
Vancouver
Feng J, Lin G, Wang Y. Efficacy and safety of combining TACE with atezolizumab/bevacizumab versus TACE alone: a retrospective propensity score-matched cohort study in HBV-related hepatocellular carcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1840779
BibTeX
@article{Feng2026,
author = {Feng, Jie and Lin, Guocheng and Wang, Yeyan},
title = {Efficacy and safety of combining TACE with atezolizumab/bevacizumab versus TACE alone: a retrospective propensity score-matched cohort study in HBV-related hepatocellular carcinoma},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1840779}
}
EUVIMED